Molecular Testing in Ovarian Cancer: Is the Time Now?

Slides:

Advertisements

Similar presentations

Fostering a Collaborative Approach in the Management of BRCA-Mutated Ovarian Cancer.

Advertisements

Bladder Cancer: A New Era in Treatment

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

State of the Art in BRCA-Mutated Ovarian Cancer

The Use of PARP Inhibitors in Breast Cancer: Challenges and Opportunities.

Immunotherapies: Key Considerations in the Identification and Management of irAEs.

Evolving Paradigms in the Management of HR-Positive Breast Cancer

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

Applying Biosimilars in Hematologic Cancers

Improving Survival in Glioblastoma Multiforme

Targeting FLT3 Mutations in Acute Myeloid Leukemia

Advances in Managing Inhibitors in Patients With Hemophilia A

PARP Inhibition: The New Frontier in Recurrent Ovarian Cancer

BRCA, HRR Deficiency, and PARP Inhibitors

The Nurse View.

Progression After Cancer Immunotherapy in Advanced NSCLC

MOCA Living Well: Understanding PARP Inhibitors in Ovarian Cancer

New Standards of Care in ALK-Translocated Advanced NSCLC

PARP and Other DNA Damage Repair Inhibitors in Solid Tumors: An Update

Mutations and AML: Sampling, Assays, and Interpreting Results

Activity Goals. Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?

Induction Chemotherapy for Patients With High-Risk or Secondary AML

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

PARP Inhibitors and Cancer: What Do You Need to Know?

BTK Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma

Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer.

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

The Nurse View.

Counseling Patients About Germline BRCA Mutations

Immunotherapy in Pancreatic Cancer: Thinking Outside the Box

Optimizing Management of Advanced Bladder Cancer

Managing gBRCA-Positive Metastatic Breast Cancer

Individualizing Care in Ovarian Cancer

Addressing Challenges in Factor VIII Inhibitors in Children With Hemophilia.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Evaluating Next-Generation BTK Inhibitors

Case Studies in Unresectable Hepatocellular Carcinoma

Targeting BTK Signaling in B-Cell Malignancies

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Immunotherapy for cSCC

The JAK-STAT Pathway and Graft-vs-Host Disease

Optimizing Frontline Care for Older Patients With Multiple Myeloma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

How to Effectively Manage Patients With Cutaneous Squamous Cell Carcinoma.

Advancing Care Across the Spectrum of Pancreatic Cancer

PARP Inhibitors and Ovarian Cancer: What Did Data From Washington, DC, Tell Us?

Expert Insights Into the Latest Treatment of Advanced Soft-Tissue Sarcoma.

Evolving Concepts in the Management of Head and Neck Cancers

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Updates in the Management of Acute Promyelocytic Leukemia

Maintenance Therapy in Advanced Ovarian Cancer

Getting to Grips With the Science of CGRP and Migraine

Advances in Immunotherapy for Peanut Allergy

Immune Checkpoint Inhibitors in Lung Cancer

PARP Inhibitors.

Locally Advanced Lung Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Evaluating BTK Inhibitors in CLL

All for One: Multidisciplinary Management in EGFR-Mutated NSCLC

This program will include a discussion of off-label treatment and investigational agents not approved by the Food and Drug Administration for use in the.

Novel Concepts in the Management of RCC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.

Checkpoint Inhibitors in First-Line Advanced NSCLC

CDK4/6 Inhibitors.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

Immune Checkpoint Inhibitors in Lung Cancer

Presentation transcript:

Molecular Testing in Ovarian Cancer: Is the Time Now?

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Basic Concepts

Overview of BRCA1 and BRCA2

Homologous Recombination Repair

Germline vs Somatic Mutations

Single- vs Multigene (Panel) Testing

Genetic Testing: Timing Faculty Recommendations

Case Study: Carla

Factors to Consider for Genetic Testing

Importance of Genetic Counseling

Case Study: Carla (cont)

Approach Upon Recurrence Faculty Recommendations

Case Study: Carla (cont)

PARP Inhibitors Overview

Predictors of PARP Activity

Olaparib in BRCAmut Advanced OC

Maintenance Olaparib vs Placebo SOLO2/ENGOT-OV21

Rucaparib in BRCAmut High-Grade OC Study 10 and ARIEL2 Combination Analysis

Rucaparib in gBRCAmut and sBRCAmut ARIEL2, Phase 2

Niraparib in HRD+ Advanced OC After Response To Platinum-Based Chemotherapy

Key Takeaways

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)